Ander Estella-Hermoso de Mendoza

Ander Estella-Hermoso de Mendoza

Auto-generated profile, based on publicly available information

Ander Estella-Hermoso de Mendoza

Department of Pharmacy and Pharmaceutical Technology, School of Pharmacy, University of Navarra, E-31008, Spain

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2011 in Journal of Controlled Release
Verified
Journal Article
Closed access
AMAnder Estella-Hermoso de Mendoza
Ander Estella-Hermoso de Mendoza
VPVeronique Préat
Veronique Préat
FMFaustino Mollinedo
Faustino Mollinedo
María J. Blanco PrietoMaría J. Blanco Prieto
María J. Blanco Prieto

26 April 2010 in Oncogene
Verified
Journal Article
Closed access
FMF Mollinedo
F Mollinedo
JIJ de la Iglesia-Vicente
J de la Iglesia-Vicente
CGC Gajate
C Gajate
AMA Estella-Hermoso de Mendoza
A Estella-Hermoso de Mendoza
JVJanny A Villa-Pulgarin
Janny A Villa-Pulgarin
María J. Blanco PrietoMaría J. Blanco Prieto
María J. Blanco Prieto


5 September 2012 in Expert Opinion on Drug Delivery
Verified
Journal Article
Closed access
BLBeatriz Lasa-Saracibar
Beatriz Lasa-Saracibar
AMAnder Estella-Hermoso de Mendoza
Ander Estella-Hermoso de Mendoza
MGMelissa Guada
Melissa Guada
CDCarmen Dios-Vieitez
Carmen Dios-Vieitez
María J. Blanco PrietoMaría J. Blanco Prieto
María J. Blanco Prieto
Introduction: Cancer is a leading cause of death worldwide and it is estimated that deaths from this disease will rise to over 11 million in 2030. Most cases of cancer can be cured with surgery, radiotherapy or chemotherapy if they are detected at an early stage. However, current cancer therapies are commonly associated with undesirable side effects, as most chemotherapy treatments are cytotoxic and present poor tumor targeting. Areas covered: Lipid nanoparticles (LN) are one of the most promising options in this field. LN are made up of biodegradable generally recognized as safe (GRAS) lipids, their formulation includes different techniques, and most are easily scalable to industrial manufacture. LN overcome the limitations imposed by the need for intravenous administration, as they are mainly absorbed via the lymphatic system when they are administered orally, which improves drug bioavailability. Furthermore, depending on their composition, LN present the ability to cross the blood–brain barrier, thus opening up the possibility of targeting brain tumors. Expert opinion: The drawbacks of chemotherapeutic agents make it necessary to invest in research to find safer and more effective therapies. Nanotechnology has opened the door to new therapeutic options through the design of formulations that include a wide range of materials and formulations at the nanometer range, which improve drug efficacy through direct or indirect tumor targeting, increased bioavailability and diminished toxicity.

31 March 2010 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
FMFaustino Mollinedo
Faustino Mollinedo
JIJanis de la Iglesia-Vicente
Janis de la Iglesia-Vicente
CGConsuelo Gajate
Consuelo Gajate
AMAnder Estella-Hermoso de Mendoza
Ander Estella-Hermoso de Mendoza
JVJanny A Villa-Pulgarin
Janny A Villa-Pulgarin
María J. Blanco PrietoMaría J. Blanco Prieto
María J. Blanco Prieto
Purpose: Mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL) remain B-cell malignancies with limited therapeutic options. The present study investigates the in vitro and in vivo effect of the phospholipid ether edelfosine (1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine) in MCL and CLL. Experimental Design: Several cell lines, patient-derived tumor cells, and xenografts in severe combined immunodeficient mice were used to examine the anti-MCL and anti-CLL activity of edelfosine. Furthermore, we analyzed the mechanism of action and drug biodistribution of edelfosine in MCL and CLL tumor-bearing severe combined immunodeficient mice. Results: Here, we have found that the phospholipid ether edelfosine was the most potent alkyl-lysophospholipid analogue in killing MCL and CLL cells, including patient-derived primary cells, while sparing normal resting lymphocytes. Alkyl-lysophospholipid analogues ranked edelfosine > perifosine ≫ erucylphosphocholine ≥ miltefosine in their capacity to elicit apoptosis in MCL and CLL cells. Edelfosine induced coclustering of Fas/CD95 death receptor and rafts in MCL and CLL cells. Edelfosine was taken up by malignant cells, whereas normal resting lymphocytes hardly incorporated the drug. Raft disruption by cholesterol depletion inhibited drug uptake, Fas/CD95 clustering, and edelfosine-induced apoptosis. Edelfosine oral administration showed a potent in vivo anticancer activity in MCL and CLL xenograft mouse models, and the drug accumulated dramatically and preferentially in the tumor. Conclusions: Our data indicate that edelfosine accumulates and kills MCL and CLL cells in a rather selective way, and set coclustering of Fas/CD95 and lipid rafts as a new framework in MCL and CLL therapy. Our data support a selective antitumor action of edelfosine. Clin Cancer Res; 16(7); 2046–54. ©2010 AACR.

1 August 2009 in Journal of Biomedical Nanotechnology
Verified
Journal Article
Closed access
AMAnder Estella-Hermoso de Mendoza
Ander Estella-Hermoso de Mendoza
MCMiguel A. Campanero
Miguel A. Campanero
FMFaustino Mollinedo
Faustino Mollinedo
María J. Blanco PrietoMaría J. Blanco Prieto
María J. Blanco Prieto
More than half of all people diagnosed with cancer receive chemotherapy. Unfortunately, most chemotherapy drugs cannot tell the difference between a cancer cell and a healthy cell. In this sense, some other drawbacks often encountered with antineoplastic compounds, such as poor stability and specificity and a high occurrence of drug-resistant tumor cells may be overcome to some degree by incorporating them into drug delivery systems. Solid Lipid Nanoparticles (SLN) have arisen considerable interest in recent years. These are particles of submicron size made from a lipid matrix that is solid at room and body temperature. Moreover, the biodegradable and biocompatible nature of SLN makes them less toxic than other nanoparticulate systems. SLN are capable of encapsulating hydrophobic and hydrophilic drugs, and they also provide protection against chemical, photochemical or oxidative degradation of drugs, as well as the possibility of a sustained release of the incorporated drugs. Along with these last issues, the feasibility of scaling up for large scale production and the low cost of lipids as compared to biodegradable polymers or phospholipids have favoured their use as potential drug delivery systems. This review focuses on the recent advances in SLN as carriers for chemotherapeutic agent delivery.